Researchers also found pairing participation in Livongo for Diabetes with lifestyle coaching regimens provided by Restore Health empowers individuals to lose weight and further improve their blood glucose.
Use of Livongo for Diabetes alone improved blood glucose control for people with T2D with a decrease in mean estimated HbA1c from 8.5% to 7.5% (p=0.01). Study participants also experienced clinically meaningful improvement in their sense of empowerment and well-being about managing their diabetes.
Researchers examined if lifestyle coaching could help people with T2D. The study evaluated 330 eligible participants with T2D who used Livongo for Diabetes for at least 80 days between October 2014, and February 2016. Participants had a BMI ≥ 25 but had not yet achieved their target level of glucose control (estimated HbA1c < 6.5%).
Lifestyle coaching included guidance in the areas of nutrition, exercise, sleep, and stress. The primary study outcome was glucose control as measured by estimated A1c. Other outcomes assessed included weight, mean blood glucose and cost-effectiveness of the interventions.
The group receiving the most intensive coaching (average of 4 coaching interactions per week) experienced the greatest weight loss over the 12-week intervention period (mean weight loss of 9.7 lbs and mean eA1c reduction of 0.7%, which tracks average blood glucose and HbA1c estimation in real time).
Restore Health, powered by privately-held Boston, Massachusetts-based biotech company Zillion's intuitive technology and live human care teams, is a cost-effective, multi-chronic condition management programme.
Zillion has collected over 100 million data points from over 500,000 users to power the identification of choice patterns that influence and manage high-risk factors for better outcomes, higher quality of care, and lower costs, leading to a powerful consumer experience.
Livongo Health's empowers people with chronic conditions to live better and healthier lives. The company's diabetes prevention, and diabetes and hypertension offerings, drive behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact.
AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
Alltrna granted approval for first-in-human clinical trial of AP003
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
Natera study shows Signatera MRD may help select breast cancer patients for non-surgical management
AstraZeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia
Galapagos and Gilead expand collaboration to advance T cell engager programme
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Delonix Bioworks launches Phase 1 trial of next-generation MenB OMV vaccine DX-104
Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
Fusion Antibodies signs GBP250,000 IP transfer deal with Finn Therapeutics